Moderna, a drugmaker with just a single product to its name, has become perhaps the best-known biotech in the world over the past four months, with nearly 100 million doses of its Covid-19 vaccine administered in the U.S. alone.
Yet investors don’t seem to know what to make of it anymore, and the stock is stuck in a spin cycle.
In the first…
